Recovery of altered diabetic myofibroblast heterogeneity and gene expression associated with CD301B+ macrophages by Haas, MaryEllen R et al.
Himmelfarb Health Sciences Library, The George Washington University 
Health Sciences Research Commons 
Biochemistry and Molecular Medicine Faculty 
Publications Biochemistry and Molecular Medicine 
11-24-2021 
Recovery of altered diabetic myofibroblast heterogeneity and 
gene expression associated with CD301B+ macrophages 
MaryEllen R. Haas 
George Washington University 
Darlene V. Nguyen 
George Washington University 
Brett A. Shook 
George Washington University 
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs 
 Part of the Molecular Biology Commons 
APA Citation 
Haas, M. R., Nguyen, D. V., & Shook, B. A. (2021). Recovery of altered diabetic myofibroblast heterogeneity 
and gene expression associated with CD301B+ macrophages. Biomedicines, 9 (12). http://dx.doi.org/
10.3390/biomedicines9121752 
This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at 
Health Sciences Research Commons. It has been accepted for inclusion in Biochemistry and Molecular Medicine 
Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, 
please contact hsrc@gwu.edu. 
biomedicines
Article
Recovery of Altered Diabetic Myofibroblast Heterogeneity and
Gene Expression Are Associated with CD301b+ Macrophages
MaryEllen R. Haas 1 , Darlene V. Nguyen 1 and Brett A. Shook 1,2,*


Citation: Haas, M.R.; Nguyen, D.V.;
Shook, B.A. Recovery of Altered
Diabetic Myofibroblast
Heterogeneity and Gene Expression
Are Associated with CD301b+
Macrophages. Biomedicines 2021, 9,
1752. https://doi.org/10.3390/
biomedicines9121752
Academic Editor: Jun Lu
Received: 7 October 2021
Accepted: 22 November 2021
Published: 24 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences,
The George Washington University, Washington, DC 20037, USA; mehaas@gwu.edu (M.R.H.);
darlene@gwu.edu (D.V.N.)
2 Department of Dermatology, School of Medicine and Health Sciences, The George Washington University,
Washington, DC 20037, USA
* Correspondence: brettshook@gwu.edu
Abstract: Diabetic wound healing is associated with impaired function and reduced numbers of my-
ofibroblasts, a heterogeneous cell population with varying capacities to promote repair. To determine
how diabetes alters myofibroblast composition, we performed flow cytometry and spatial tissue anal-
ysis of myofibroblast subsets throughout the healing process in diabetic (db/db) and control (db/+)
mouse skin. We observed reduced numbers of profibrotic SCA1+; CD34+; CD26+ myofibroblasts in
diabetic wounds five days after injury, with decreased expression of fibrosis-associated genes com-
pared to myofibroblasts from db/+ mouse wounds. While the abundance of myofibroblasts remained
reduced in db/db mouse wounds compared to controls, the altered myofibroblast heterogeneity
and gene expression in diabetic mice was improved seven days after injury. The natural correction
of myofibroblast composition and gene expression in db/db wound beds temporally corresponds
with a macrophage phenotypic switch. Correlation analysis from individual wound beds revealed
that wound healing in control mice is associated with CD206+ macrophages, while the rescued
myofibroblast phenotypes in diabetic wounds are correlated with increased CD301b+ macrophage
numbers. These data demonstrate how diabetes impacts specific subsets of myofibroblasts and
indicate that signaling capable of rescuing impaired diabetic wound healing could be different from
signals that regulate wound healing under nonpathological conditions.
Keywords: myofibroblast; macrophage; wound healing; diabetes
1. Introduction
Wound healing requires communication between numerous tissue-resident and infil-
trating cells [1,2]. Dynamic changes within these signaling networks help regulate three
overlapping phases that govern wound healing: inflammation, proliferation, and tissue
remodeling. Diabetes is associated with impaired wound healing that is characterized by
delayed early activation of proinflammatory immune cells and subsequent persistence
of proinflammatory immune cells at later time points after injury [3–6]. This hinders
the progression into the proliferation phase, preventing wound healing from occurring
efficiently.
Shortly after the injury, numerous cells produce proinflammatory factors that support
the infiltration of inflammatory macrophages and neutrophils [7–9]. These myeloid cells
clear foreign pathogens and cellular debris and perpetuate inflammation [2,7,10] before acti-
vating the initial processes that promote repair [11–13]. As inflammation resolves, changes
in the gene expression profile of local macrophages support entry into the proliferation
phase [10,12,14,15]. Macrophage-derived factors promote the migration and proliferation
of keratinocytes, fibroblasts, and endothelial cells to repair the injured tissue [11,13,15–17].
Activated fibroblasts, or myofibroblasts, are the leading producers of extracellular matrix
(ECM) molecules necessary to strengthen the repaired tissue [18–20]. Lineage tracing and
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cell surface profiling have defined multiple subsets of functionally distinct myofibrob-
lasts in wound beds [21–25]. We have previously shown that myofibroblasts expressing
SCA1, CD34, and CD29 are enriched with the potential to generate mature ECM [23]. This
population is Engrailed-lineage traced and expresses CD26, characteristic of scar-forming
fibrogenic myofibroblasts in both mice and humans [22,23,26,27]. This population of my-
ofibroblasts is diminished in wounds of aged mice and undergoes significant age-related
changes in its transcriptome [23], underscoring the need to understand how this population
is altered under different pathological conditions.
Diabetic wound healing is associated with reduced numbers of alpha-smooth muscle
actin (SMA)-expressing myofibroblasts and changes in myofibroblast gene expression that
contribute to reduced ECM deposition [28–32]. While impaired diabetic wound healing
can result in wounds that persist for months to years in humans [33], repair in diabetic mice
is typically delayed, with wounds closing by 14–28 days based on the original size and
location of the injury [34–36]. Recent reports have begun to characterize functional groups
of myofibroblasts that are present during different types of wound healing responses in
mice and humans [22,23,37–40], including multiple groups defining subsets of fibroblasts
in human diabetic wounds [39,40]. Though these single endpoint reports provide large
datasets that can reveal mechanisms that contribute to impaired healing, additional multi-
endpoint studies are needed to define how diabetes alters wound bed myofibroblast
composition and function over time and to define mechanisms that support repair in a
diabetic state.
In this study, we investigated how diabetes alters myofibroblast heterogeneity and
gene expression using diabetic db/db mice. We observed delayed appearance of fibrogenic
SCA1+; CD29+; CD26+ myofibroblasts in diabetic mouse wound beds compared to control
mice. This altered myofibroblast composition was associated with decreased gene expres-
sion of repair- and fibrosis-associated genes in day five wound beds. Surprisingly, seven
days after injury, the relative abundance of SCA1+; CD29+; CD26+ myofibroblasts became
more prevalent, and diabetes-associated changes in gene expression within this cellular
population were not detected. Correlation analyses from individual wound beds revealed
that a robust population of CD26- and SMA-expressing myofibroblasts were associated
with the emergence of CD206+ macrophages in control mice. However, the diminished
disease phenotype was positively correlated with the number of macrophages that express
CD301b. Our results demonstrate that myofibroblast heterogeneity and gene expression
in diabetic mice bias the wound environment towards a non-reparative state and that the
natural correction of the disease phenotype is observed with increased numbers of CD301b+
macrophages that have been shown to support the proliferation of SCA1+; CD29+; CD26+
myofibroblasts in control conditions [23]. These data reveal that the ability of diabetic mice
to heal may depend on different factors than what coordinates repair in control animals
and highlight the importance of identifying mechanisms that promote tissue repair in a
diabetic state.
2. Materials and Methods
2.1. Mice
Animal care and experiments were performed following the guidance of George
Washington University’s Institutional Animal Care and Use Committee (IACUC). Mice of
the B6.BKS(D)-Leprdb/J (Jackson Laboratories, Bar Harbor, ME, USA, Stock #000697; db/db
mice) strain with a spontaneous leptin receptor mutation resulting in hyperinsulinemia,
hyperglycemia, and obesity were used for these studies, and db/+ littermates were used
as controls. During the telogen phase of the hair cycle, male mice (7–9 weeks old) were
anesthetized, dorsal fur was shaved, and four full-thickness skin excision wounds were
inflicted by biopsy punch (Integra Miltex, Rietheim-Weilheim, Germany), 3–4 mm apart,
on either side of the spine between the shoulders and hips as previously described [23,41].
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2.2. Immunofluorescence and Wound Bed Analysis
After euthanasia, wounds were harvested, embedded in optimal cutting temperature
(O.C.T.) compound, frozen, and sectioned using a cryostat (Microm, Boise, ID, USA). To
identify the center of wounds, the entirety of the embedded tissue was sectioned from
wound edge to wound edge. Sequential tissue sections were distributed across approxi-
mately ten slides to allow the center of the wound to be identified on each slide. Tissue
cryosections of 16 or 40 µm thickness were fixed with 4% formaldehyde and stained
with the following antibodies: CD26 (Abcam, Waltham, MA, USA, 1:250; Novus, 1:50),
CD29 (R&D Systems, 1:50), CD45 (Biolegend, 1:500), CD206 (Biolegend, San Diego, CA,
USA 1:500), CD301b (eBioscience, San Diego, CA, USA, 1:100), ER-TR7 (Abcam, 1:500),
iNOS (Thermofisher, Waltham, MA, USA, 1:100), PU.1 (Cell Signaling, Danvers, MA, USA,
1:100), and SMA (Abcam, 1:400). For histological analysis of each wound, the two central-
most wound bed sections were imaged using Zeiss AxioImager M2 (Zeiss, Oberkochen,
Germany) with Orca camera (Hamamatsu, Hamamatsu, Japan), analyzed as described
below, and averaged together as a single wound bed value. The abundance of SMA+
and ER-TR7+ fibroblasts was calculated using the Color Range feature of Adobe Photo-
shop to determine the percentage of wound bed pixels occupied by fluorescent staining.
ECM proteins were quantified by the previously described corrected total fluorescence
calculation [42,43] using ImageJ software (National Institutes of Health, Bethesda, MD,
USA). Spatial mapping of fibroblast subsets based on CD45 (negative), CD26, and CD29
expression was performed in MATLAB as previously detailed [23]. Wound bed CD26 im-
munostaining was assessed by mean gray fluorescence (sum of pixel gray values divided
by the total number of pixels selected) of the wound bed within CD45-negative cells using
ImageJ. Cell counts were manually tabulated in ImageJ software.
2.3. Fluorescence-Activated Cell Sorting Analysis
Intact dorsal mouse skin or wound beds were harvested, minced, and digested using
Liberase TM to release single cells. Cells were resuspended in FACS staining buffer (1%
BSA in PBS with 2 mM EDTA) and stained with the following antibodies for 30 min on ice:
CD45-PE-Cy7 (eBioscience, 1:2000), CD31-APC-Fire750 (Biolegend 1:1000), CD29-Alexa700
(eBioscience, 1:400), CD34-Pacific Blue (BD Bioscience, 1:50), Sca1-V500 (eBioscience, 1:500),
CD26-PE-Cy7 (Biolegend, 1:500), CD9-APC (BD Bioscience, 1:100), and CD9-FITC (eBio-
science, 1:100). Samples were analyzed on a BD Aria III with FACSDiva software (BD
Biosciences, San Jose, CA, USA), and gating and analyses were completed with FlowJo
software (BD Biosciences).
2.4. RNA Extraction and qRT-PCR
To determine differential gene expression between conditions, FACS-purified myofi-
broblasts were sorted into DMEM containing 10% FBS. Cells were pelleted by centrifu-
gation. Using TRIzol LS (Invitrogen, Waltham, MA, USA), samples were digested and
phase-separated; RNA was extracted in the aqueous phase and purified using the RNeasy
Plus Micro Kit (Qiagen, Hilden, Germany). A Superscript III First-Strand Synthesis Kit
(Invitrogen) was used to generate cDNA proportionally to the isolated RNA. Gene targets
were amplified by qRT-PCR on a LightCycler 480 (Roche, Basel, Switzerland) with SYBR
PowerTrack Green master mix (Applied Biosystems, Beverly, MA, USA) and gene-specific
primers listed in Supplemental Table S1. Reported results consist of levels of target mRNA
normalized to β-actin. Data represent the average of biological samples (n = 3–4 mice)
calculated from technical qPCR triplicates.
2.5. Statistics
To determine significance between experimental groups, comparisons were made
using Student’s t-test. Analyses across multiple groups were made using a one-way analysis
of variance with Bonferroni’s post hoc test using GraphPad Prism for Mac (GraphPad
Software, La Jolla, CA, USA) with significance set at p < 0.05.
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3. Results
3.1. Diabetic Murine Wound Beds Exhibit Delayed Myofibroblast Population
The rate of skin repair is influenced by many factors, such as hair follicle stage, sex,
and type of wound [34,44,45]. To determine how obesity and diabetes associated with
db/db mice impact fibroblast/myofibroblast population of wound beds in our model
(4 mm full-thickness dorsal skin excision), we harvested wounds from control (db/+) and
diabetic (db/db) mice 5, 7, and 14 days post wounding (PW). In control mice, these time
points represent periods of robust proliferation and migration of cells that repair the tissue
(five days PW), complete repopulation of tissue that results in a hypercellular wound bed
(seven days PW), and pruning of the hypercellular wound bed to more closely represent
uninjured tissue (14 days PW) [42,46]. Tissue sections from the center of the wounds were
immunostained for SMA to label myofibroblasts and ER-TR7 to broadly label fibroblasts.
In db/db mice, there was approximately a 50% reduction in the percentage of wound bed
area occupied by SMA+ and ER-TR7+ fibroblasts in wound beds five and seven days after
injury (Figure 1A–D). This was associated with decreased expression in wound beds of
genes associated with fibrosis, such as Col1, Col3, Mmp2, Pdgfa, and Vegfa (Figure 1E), and
higher expression of proinflammatory cytokines such as Cxcl2 and Tnf (Figure 1F) in day
five wound beds from db/db mice compared to db/+ mice. Interestingly, there was no
detectable difference in the area of wound bed occupied by SMA+ and ER-TR7+ fibroblasts
in 14-day wounds (Figure 1A–D), suggesting that the delayed fibroblast population was
ameliorated by 14 days after injury in our model.
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Figure 1. yofibroblast population is delayed in diabetic mouse skin repair. (A–D) Sections from the center of wound beds
(WB) from db/+ and db/db mice were analyzed for the myofibroblast population at days 5, 7, and 14 post-wounding (PW).
(A,B) Images (A) and quantification (B) of tissue sections immunostained for SMA. (C,D) Images (C) and quantification
(D) of tissue sections immunostained for ER-TR7. (E) Expression of genes associated with wound healing and fibrosis
in db/db wounds compared to db/+ wounds, five days after injury. (F) Expression of genes associated with wound
inflammation in 5-day PW db/db wounds compared to 5-day PW db/+ wounds. White dashed lines delineate wound
edges. Orange dashed lines define the border between the wound bed and subcutaneous white adipose tissue (SWAT).
Scale bars, 250 µm. n = 4 for each condition. Error bars indicate mean ± SEM. * p < 0.05, *** p < 0.001.
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3.2. Fibroblast Heterogeneity Is Altered in Diabetic Wound Beds
While a reduction in proliferation phase myofibroblasts has been documented in
wound beds from diabetic mice [28], little is known about how individual subsets of my-
ofibroblasts are altered by diabetes. We have previously described multiple subsets of
myofibroblasts that can be identified using cell surface marker expression of CD29, SCA1,
and CD34 [23,41]. These myofibroblast subsets are functionally distinct, with different
propensities to generate and modify ECM [23]. In particular, a subset of myofibroblasts
enriched with CD34, SCA1, and CD26 is associated with efficient wound healing, whereas
SCA1-; CD29High myofibroblasts were associated with impaired healing [23]. Using flow
cytometry, we investigated if diabetes alters the relative abundance of CD34+; SCA1+, and
CD29High mesenchymal cells in the skin and determined if colocalization with profibrotic
markers CD9 [47] and CD26 [22] was different in db/db skin compared to db/+ control skin
(Figure S1A). We did not observe a statistically significant difference in the relative abun-
dance of CD34+; SCA1+ and CD29High mesenchymal cells in uninjured skin (Figure 2A),
and the percentage that colocalized with CD9 was similar in diabetic and control samples
(Figure S1B). Interestingly, a greater percentage of CD29High cells colocalized with the
profibrotic marker CD26 in uninjured db/db skin versus uninjured db/+ skin (Figure 2A).
While these mesenchymal cell populations colocalize with markers of profibrotic fibroblasts,
very few cells in intact db/db or control skin express the PU.1 transcription factor that is
expressed by activated profibrotic fibroblasts [48] (Figure S1B), suggesting that diabetic
skin fibroblasts are not in an active fibrotic transcriptional state. Additionally, inherent
differences in gene expression between CD29High and CD34+; SCA1+ fibroblasts are similar
in db/db skin compared to what is observed in other control mouse strains [23], such as
CD34+; SCA1+ fibroblasts expressing higher levels of Ccl2 and Il6 with lower expression
of Il1b and Pdgfa, compared to CD29High fibroblasts (Figure S1C). These data indicate that
diabetic skin is not depleted of fibrogenic fibroblasts prior to the injury.
To determine how diabetes alters the composition of wound bed myofibroblasts, we
examined the relative abundance of CD34+; SCA1+, and CD29High myofibroblast subsets
in wound beds five days post-wounding (PW) in db/+ and db/db mice. Interestingly,
wound beds from diabetic mice exhibited a ~25% greater enrichment for CD29High cells and
lacked significant enrichment for CD34+; SCA1+ myofibroblasts compared to control mice
(Figure 2B,C). These results were similar to what we have previously observed in wounds
from aged mice [23], which also are associated with delayed myofibroblast population
and impaired wound healing. After the injury, a greater percentage of CD34+; SCA1+
myofibroblasts express CD9 while retaining colocalization with CD26. The percentage of
CD34+; SCA1+, and CD29High myofibroblasts that colocalize with CD9 and CD26 was
similar in diabetic and control mice, except more CD29High myofibroblasts colocalize with
CD26 (Figure S1D), similar to what is observed in uninjured skin (Figure 2A). In line with
samples from uninjured skin (Figure S1C) and our previously published data [23], CD34+;
SCA1+ and CD29High wound bed myofibroblasts had unique gene expression profiles. For
instance, CD34+; SCA1+ myofibroblasts had greater expression of Fgf7, Fn1, and Il6, while
CD29High myofibroblasts had greater expression of Pdgfa and Tnc (Figure S1E), suggesting
a functional difference between myofibroblast subsets.
In wild-type strain mice, CD29High myofibroblasts are typically biased to the super-
ficial wound edges [23]. To determine if there are spatial biases to the distribution of
CD34+; SCA1+; CD26+ and CD29High myofibroblasts in db/db mouse wound beds, we
assessed the distribution of nonimmune (CD45 negative) cells in wound beds based on
the expression of CD29 and CD26 in wounds from db/+ and db/db mice (Figure 2D).
Similar to wild-type strains, we observed a superficial and wound edge bias of CD29High
myofibroblasts in wound beds five days PW (Figure 2E). Interestingly, while there was
a delay in CD26-expressing myofibroblasts populating the wound beds of db/db mice,
the spatial distribution mirrored that of db/+ at earlier time points (Figure 2E). While
there is a clear reduction in the abundance of myofibroblasts seven days PW in wounds
of diabetic mice compared to earlier time points in control mice (Figure 1A), there was a
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surprising similarity in myofibroblast subset distribution and relative abundance between
7-day db/db wound beds and 5-day db/+ wound beds (Figure 2C,E), suggesting that
signaling in diabetic wounds begins to promote repair during this time to ameliorate the
impaired response.
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Our data support that diabetes is associated with fewer myofibroblasts that have pro-
fibrotic potential at both five and seven days after injury. Though surface marker expres-
sion is highly predictive of cellular function in control mice, disease-associated changes in 
gene expression can lead to impaired cellular activation and function [49,50]. To 
Figure 2. Myofibroblast composition is altered in diabetic mouse wounds. (A) Quantification from flow cytometry analysis
of the relative abundance of CD34+; SCA1+ and CD29High fibroblasts in db/db uninjured (NW) skin compared to db/+
skin and the percentage that colocalized with CD26. (B) Flow plots of CD45-, CD31-lineage negative, Sytox-, single cells
from wound beds five days post-wounding (PW) displaying different populations of myofibroblasts based on CD34 and
CD29 levels. (C) Quantification of the abundance of CD34+; Sca1+ and CD29High myofibroblasts in db/+ and db/db wound
beds five days and seven days PW. (D) Workflow to spati lly quantify CD29 and CD26 signal intensities in woun bed
sec s immunostained for CD26, CD29, and CD45. (E) Quantification and cartoon epresentations of the av rage spatial
distribution of CD26 nd CD29 signals in wound beds five days and seven days after injury in db/+ and db/db mice. Scale
bars, 250 µm. n = 3–5 for each condition. Error bars indicate mean ± SEM. * p < 0.05, ** p < 0.01.
3.3. Corrected Profibrotic Gene Expression Precedes Recovery of Myofibroblast Numbers in
Diabetic Wound Beds
Our data suppor that diabet s is associa d with fewer myofibroblasts that have
profibrotic potential at both five and seven days after injury. Though surfa e marker
expression is highly pr dictive of cellular function in control mice, disease-associated
changes in gene expression can lead to impaired cellular activation and function [49,50]. To
determine if myofibroblasts in 5-day wounds from db/+ and db/db mice are activated to
be profibrotic, we quantified the number of wound bed cells that express the transcription
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factor PU.1. Not only did wound beds from db/db mice have significantly fewer PU.1+
cells compared to db/+ controls, but there was a significant reduction in the percentage
of total cells that colocalized with PU.1 (~60% in db/+ vs. 15% in db/db) (Figure 3A–C).
While previous reports have implicated CD26-expressing myofibroblasts as drivers of
ECM production and scar formation [22], immunofluorescent staining of tissue sections
five days PW with CD26 and PU.1 did not reveal strong correlations between CD26 and
PU.1 co-expression within the same cells (Figure 3D), suggesting further heterogeneity or
different active states may exist within CD26+ myofibroblasts.
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density of PU.1+ cells and percentage of DAPI+ nuclei in tissue sections from db/+ and db/db wound beds five days PW.
Arrows indicate CD26+; PU.1+ cells, white arrowheads indicate CD26-; PU.1+ cells, and yellow arrowheads indicate CD26+;
PU.1- cells. (D) Image from the center of a day five wound bed immunostained for CD26 and PU.1. Scale bars, 75 µm. (E,F)
Quantification of gene expression of CD34; SCA1+ and CD29High myofibroblasts from db/db mice five days (E) and seven
days (F) PW normalized to the same myofibroblast population from db/+ wounds from the same time point. n = 3–6 for
each condition. Error bars indicate mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
To interrogate how diabetes impacts the function of specific myofibroblast subsets,
we FACS-isolated CD34+; SCA1+ and CD29High myofibroblasts from wound beds five
days PW and examined the expression of genes related to myofibroblast function. We
did not observe diabetes-associated changes in gene expression of cellular identity genes,
such as Itga5, Ly6a (SCA1), and Thy1; however, diabetes was associated with changes in
gene expression of ECM- and inflammation-related genes. Interestingly, gene expression
of ECM components, such as Col1, Col3, Fn1, Mmp2, and Tnc, was significantly reduced
in diabetic CD34+; SCA1+ myofibroblasts compared to db/+ controls; however, gene
expression in ECM molecules was not significantly altered in CD29High myofibroblasts
from db/db mice (Figure 3E). We further explored ECM components through analysis
of tissue sections in uninjured skin and wound beds. While tenascin C is not present
in uninjured skin, we observed reduced immunofluorescent staining of fibronectin in
db/db skin compared to db/+ skin (Figure S2A,B). Interestingly, after injury, the relative
intensity of fibronectin staining is similar between db/db and db/+ mice (Figure S2C,D),
and tenascin C levels are lower in db/db wounds compared to db/+ controls at both five
and seven days PW (Figure S2E,F). These results are in line with our observed changes
in gene expression and previous reports demonstrating that diabetes is associated with
normal levels of fibronectin [32] but decreased levels of tenascin C after injury.
To further explore how diabetes alters fibroblast function during the proliferation
phase, we examined gene expression of ECM molecules and secreted signaling molecules
in SCA1+ and CD29High myofibroblasts seven days after injury. Surprisingly, we ob-
served few significant changes in gene expression within the SCA1+ myofibroblast subset
(Figure 3F). While we observe reduced ECM molecule expression in CD29High myofibrob-
lasts (Figure 3F), many of these genes are more enriched in CD34; SCA1+ myofibroblasts
(Figure S1D) [23]. These data indicate that diabetes-associated changes in gene expression
are less pronounced in CD34+; SCA1+ myofibroblasts at the same time post-wounding as
when the number of CD34+; SCA1+; CD26+ myofibroblasts increases (Figure 2C,E).
3.4. A Macrophage Phenotype Switch Is Concomitant with Changes in Wound Bed Myofibroblasts
Our data reveal a similar gene expression profile in SCA1+ myofibroblasts and a
correction of myofibroblast heterogeneity seven days after injury in our wound model
(Figure 2C). This indicates that the wound environment of db/db mice is capable of
rescuing CD34+; SCA1+ myofibroblast dysfunction prior to the rapid recovery in gen-
eral myofibroblast population and tissue formation that is observed by two weeks after
injury in db/db mice (Figure 1A–D). Macrophage phenotype has been correlated with
fibroblast function and wound healing outcomes in humans [40,51–54], and functional
animal studies have confirmed that anti-inflammatory (M2) macrophages support tissue
repair [17,46,55,56]. After the injury, iNOS+ inflammatory (M1) macrophages are prevalent
during the early phases of repair. As healing proceeds, the number of M1 macrophages
decreases as CD206+ M2 macrophages become the predominant phenotype. Over time,
CD206+ macrophages begin to express CD301b [46,57]. To define changes in macrophage
phenotype that are associated with rescued myofibroblast heterogeneity and function, we
quantified the number of CD206+, CD310b+, and iNOS+ macrophages in tissue sections
during tissue repair in db/+ and db/db mice (Figure 4A–C). Diabetic mice had fewer
CD206+ and CD301b+ M2 macrophages and a greater number of iNOS + M1 macrophages
five days PW. Interestingly, the relative numbers of CD206+ and iNOS+ macrophages were
not significantly different seven days after injury, corresponding with the timing of rescued
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SCA1+ myofibroblast gene expression (Figure 4A,C). These data support that a switch
in macrophage phenotype is temporally aligned with the recovery of myofibroblast gene
expression and subsequent tissue repair. Since these data examine macrophages based
general characterization of M1 and M2 subsets, it is important for future lines of research
to continue defining how individual macrophage subsets are altered by the diabetic state.
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tification from tissue sections from db/+ and db/db wounds 5, 7, and 14 days post-wounding (PW) immunostained for
anti-inflammatory macrophage marker CD206. The white dashed lines delineate the wound edges, and the orange dashed
line indicates the boundary between the wound bed and deeper subcutaneous white adipose tissue (SWAT). Scale bars,
250 µm. (B) Immunostaining images and quantification of CD301b throughout healing in db/+ and db/db wound beds.
Scale bars, 100 µm. (C) Image from the section of 5-day wound bed immunostained for iNOS nd quantification of the
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Our methodology to identify the wound center involves the repeated distribution of
subsequent tissue sections onto a set of slides. This generates a set of slides containing
tissue sections on each slide that were obtained from different locations throughout the
wound bed. On each slide, the central section of the wound can be identified based on
the size of the wound bed and various morphological characteristics of epithelial repair
(Figure 5A). Slides from the same wound bed can be processed with different antibodies
to compare the results between multiple analyses and determine which parameters are
correlated (Figure 5A). Using this system, we assessed which immune cell measurements
(Figure 4) were associated with the presence of SMA+ wound bed myofibroblasts (Figure 1),
including the ratio of CD206+ to iNOS+ macrophages (M2/M1). In day five wound beds
from db/+ control mice, the abundance of SMA+ cells was positively correlated with
the number of CD206+ macrophages and the ratio of M2/M1 macrophages (Figure 5B).
Additionally, there was no correlation with the number of iNOS+ (M1) macrophages and
a slight negative correlation with CD301b macrophages (Figure 5B). The slight inverse
correlation with CD301b+ macrophages is not surprising, considering most of the wound
bed macrophages do not begin to express CD301b until a later time point after injury [46].
These findings are similar to what is observed in various other control mouse strains.
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Interestingly, in day five wounds from db/db mice, the amount of SMA+ cells did
not correlate with the number of CD206+ macrophages but correlated with the number of
CD301b+ macrophages (Figure 5B). The positive correlation of SMA+ cells and CD301b+
macrophages persisted in diabetic wounds seven days after injury (Figure 5B). These data
suggest that the cells and possibly the signaling pathways required to promote wound
healing in diabetic mice are different from those found in control animals. We further
investigated the connection between CD301b+ macrophages and wound bed myofibroblast
populations by looking at the association of CD26 intensity (data from Figure 2) and
SMA and ER-TR7 cells abundance (Figure 1A,B) with CD301b+ macrophages. In day
five wounds from db/+ mice, CD26, SMA, and ER-TR7 levels all positively correlated
with each other, but these measurements were inversely correlated with the nu ber of
301b+ acrophages (Figure 5C). Surprisingly, the amount of CD26+ mesenchymal cells
in wound beds did not correlate with the number of SMA+ cells in day five wounds from
db/db mice (Figure 5C). Nevertheless, the abundance of CD26+, SMA+, a - 7
cells all positively correlated with the abundance of CD301b+ macrophages (Figure 5C).
By seven days PW, the relative abundance of CD26+ cells in db/db mouse wound beds
positively correlated with SMA+, ER-TR7+ and CD301b+ cell numbers (Figure 5C). These
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data provide a disease context to strengthen the previously published connection between
CD301b+ macrophages and fibrogenic CD26+ myofibroblasts [23].
4. Discussion
Progression of tissue repair into the proliferation phase has been linked to a switch
in macrophage polarization [10,40,46,51], as anti-inflammatory macrophages initiate re-
pair. Here, we revealed that diabetic mouse wounds have both fewer myofibroblasts with
fibrogenic capacity and impaired gene expression within myofibroblast subsets. Collec-
tively, these changes contribute to diminished ECM production during diabetic wound
healing [32,58]. Our 4 mm biopsy punch model of dorsal skin excision enables more rapid
recovery of wound healing defects than larger wound paradigms. This allowed us to
capture a time point in diabetic wound healing when myofibroblast numbers are still
reduced compared to controls; however, the relative abundance of myofibroblast subsets
and repair-related gene expression within each subset are not significantly different. Cor-
relation analysis revealed that efficient wound healing in control mice is associated with
CD206-expressing anti-inflammatory (M2) macrophages. This same analysis identified
that the ability of diabetic mouse wounds to rescue the impaired healing phenotype is not
associated with CD206+ macrophages but with CD301b-expressing macrophages. These
macrophages have been shown to be important for the expansion of fibrogenic wound
myofibroblasts and efficient wound healing [23,46]. These findings are supported by ani-
mal studies that demonstrated that amelioration of impaired healing could occur through
administration of (1) factors that rescue defects in early macrophage infiltration [16,59–61]
or (2) factors derived from anti-inflammatory macrophages that promote repair [23,62–67].
These data not only describe how diabetes alters myofibroblast composition and gene
expression but also differences in how wound healing in control and diabetic animals
may rely on subtle differences in anti-inflammatory macrophage subsets to support tissue
repair.
Recently, single-cell RNA-sequencing has been used to define the cellular composition
in human diabetic skin and wound samples [39,40,68]. These studies provide tremendous
insights into cellular heterogeneity and changes in gene expression between conditions;
however, additional time points throughout the healing process are needed to fully un-
derstand how the environment changes over time. This challenge is compounded by the
inability to identify a chronic or nonhealing wound patient until months after the injury [33].
At this late time point after injury, the cellular and molecular interactions dictating local
cellular responses are different than what is observed during normal acute repair [28]. Us-
ing a 4 mm dorsal skin excision wound model, we examined repair at multiple time points
during the proliferation phase to define how myofibroblast heterogeneity is altered in
db/db mice compared to db/+ control animals. The lack of CD26+; SCA1+ fibroblasts early
during the proliferation phase is consistent with what is observed with age [23,69]. Later
during the proliferation phase, CD26+; SCA1+ myofibroblasts become more abundant
than other myofibroblast subsets in diabetic wounds. This change is observed alongside
a recovery in impaired myofibroblast gene expression but prior to a broader rescue of
total myofibroblast numbers, suggesting that the wound environment can rescue impaired
healing in diabetic mice. Performing transcriptomics at multiple time points throughout the
healing process would allow future studies to explore mechanisms necessary to overcome
the diabetic environment and contribute to new therapeutic approaches.
Analyzing multiple parameters in tissue sections from the center of the same wound
beds allowed us to determine cellular events associated with improved outcomes at multi-
ple time points. This comprehensive correlation analysis revealed that diabetic wounds
with greater myofibroblast abundance, including more fibrogenic CD26+ myofibroblasts,
correlated with greater numbers of CD301b+ macrophages at both five and seven days
after injury. While this is in line with other reports [23,26,46,70], the correlation was not
detectable in our data that averaged numbers within a group, a surprising result, given
that CD301b+ cell numbers were low in 5- and 7-day wound beds from db/db mice with
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minimal variation between animals. This result reveals that averaging data groups is
susceptible to losing valuable data based on the variation within a group. Additionally,
our correlation analyses revealed that different M2 macrophage populations were associ-
ated with improved myofibroblast numbers in diabetic versus control groups. Recently,
increased attention has been given to experiments aimed at defining mechanisms that sup-
port diabetic healing in humans [39,40]. Researchers have started to rely less on data from
lean individuals and more on samples from diabetic healers as controls for studies examin-
ing impaired diabetic wound healing [5,39]. Our correlation analyses capitalized on the
variation that occurs during diabetic wound healing in mice to reveal conditions associated
with improved myofibroblast repopulation relative to wounds with more myofibroblast
dysfunction. Additional studies will be needed to determine if CD301b+ macrophages
functionally contribute to the corrected myofibroblast phenotypes during delayed diabetic
wound healing.
5. Conclusions
In summary, while murine diabetic wound healing is associated with fewer profibrotic
myofibroblasts and decreased expression of genes associated with the repair, diabetic
wounds that can heal have greater numbers of CD301b-expressing macrophages. It will
be important for future investigations to determine how factors influence the ability of
myofibroblasts to recovery, especially since the length of diabetes, size of the wound, or
animal species can impact healing rates [34,44,45,71]. Additionally, it will be critical to
determine if the same cellular and molecular mechanisms are responsible for the recovery
in different injury paradigms since slight changes in wound size can substantially impact
the contribution from specific fibroblast lineages and regenerative potential of the injury
response [24,37,41,72,73]. Since diabetic human fibroblasts undergo epigenetic changes
that are not easily rescued in culture [74], future studies are needed that explore differences
in diabetic healers and diabetic non-healers. Future human studies will be critical for
uncovering clinically relevant mechanisms that promote myofibroblast function and tissue
repair in diabetics.
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